CRISPR & machine learning for genetic disease therapeutics
Identify novel gene targets for monogenic disorders; Accelerate CRISPR screening for rare genetic conditions; Optimize gene editing efficiency using ML models; Discover therapeutic candidates for inherited retinal diseases; Enable scalable discovery of gene therapies for monogenic diseases
Founded in 2022; Early-stage VC-backed startup; Based in MBC BioLabs, San Carlos, CA; Supported by Illumina, NIH, DoD, and NVIDIA Inception Program; Stanford University CRISPR lab origin